GM3 Synthase Deficiency via the ST3GAL5 Gene
Summary and Pricing
Test Method
Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture ProbesTest Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
4255 | ST3GAL5 | 81479 | 81479,81479 | $990 | Order Options and Pricing |
Pricing Comments
Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
GM3 synthase deficiency (or Amish Infantile Epilepsy Syndrome or Salt and Pepper Mental Retardation Syndrome) is a rare infantile onset neurocutaneous disorder characterized by refractory epilepsy, severe intellectual disability, dysmorphic facial features and hyper- and hypo-pigmented skin maculae on the trunk, face, and extremities. Other variable features include scoliosis, choreoathetosis, spasticity, blindness, deafness, and abnormal EKG (Fragaki et al. 2013; Boccuto et al. 2014).
The onset of epilepsy is accompanied by profound developmental stagnation and regression. Failure to thrive, trouble feeding, and irritability are noticed in the first 2 weeks to 3 months of life. Seizure onset occurs within the first year with multiple type manifestations including generalized tonic-clonic seizures, brief tonic spasms, episodes of eye deviation or startle from sleep. EEG reveals multifocal epileptiform activity. MRI results are initially normal, but show diffuse atrophy as patients age. Mass spectrometry reveals loss of complex gangliosides (Simpson et al. 2004; Fragaki et al. 2013).
Genetics
GM3 synthase deficiency is inherited in an autosomal recessive manner and is caused by pathogenic variants in the ST3GAL5 gene which encodes GM3 synthase (sialyltransferase). Missense and nonsense variants in ST3GAL5 have been reported in patients with GM3 synthase deficiency. No large deletions/duplications in the ST3GAL5 locus have been reported. Initially described in an Old Order Amish pedigree, GM3 synthase deficiency has subsequently been reported in African-American and French families (Simpson et al. 2004; Fragaki et al. 2013; Boccuto et al. 2014).
GM3 synthase adds sialic acid to lactosylceramide, finally forming ganglioside GM3. The ganglioside GM3 is a glycosphingolipid mainly expressed in neural tissue. One study demonstrated that mitochondrial dysfunction and apoptosis occurred secondary to GM3 synthase deficiency (Fragaki et al. 2013). The authors suggest that mitochondrial defects might contribute to the ganglioside GM3 synthase deficiency phenotype and could explain the clinical similarities between GM3 synthase deficiency and respiratory chain disorders (Fragaki et al. 2013).
Clinical Sensitivity - Sequencing with CNV PG-Select
Clinical sensitivity of ST3GAL5 in a large cohort of patients with ganglioside GM3 synthase deficiency relevant phenotypes is unavailable in the literature because most of the studies are case reports. Analytical sensitivity should be high because all pathogenic variants reported to date are detectable by sequencing.
Testing Strategy
This test provides full coverage of all coding exons of the ST3GAL5 gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.
Indications for Test
ST3GAL5 testing should be considered for patients suspected to have GM3 synthase deficiency. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in ST3GAL5.
ST3GAL5 testing should be considered for patients suspected to have GM3 synthase deficiency. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in ST3GAL5.
Gene
Official Gene Symbol | OMIM ID |
---|---|
ST3GAL5 | 604402 |
Inheritance | Abbreviation |
---|---|
Autosomal Dominant | AD |
Autosomal Recessive | AR |
X-Linked | XL |
Mitochondrial | MT |
Disease
Name | Inheritance | OMIM ID |
---|---|---|
Amish Infantile Epilepsy Syndrome | AR | 609056 |
Citations
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.